The Journal of Neuroscience, January 11, 2006, 26(2):535-541; doi:10.1523/JNEUROSCI.3008-05.2006
Previous Article | Next Article 
Neurobiology of Disease
Estrogen Prevents Neuroprotection by Caffeine in the Mouse 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Model of Parkinson's Disease
Kui Xu,1
Yuehang Xu,1
Deborah Brown-Jermyn,1
Jiang-Fan Chen,2
Alberto Ascherio,3
Dean E. Dluzen,4 and
Michael A. Schwarzschild1
1Molecular Neurobiology Laboratory, Department of Neurology, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts 02129, 2Department of Neurology, Boston University School of Medicine, Boston, Massachusetts 02118, 3Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts 02115, and 4Department of Anatomy, Northeastern Ohio Universities College of Medicine, Rootstown, Ohio 44272
Epidemiological studies have strongly linked caffeine consumption with a reduced risk of developing Parkinson's disease (PD) in men. Interestingly, in women, this inverse association is present only in those who have not taken postmenopausal estrogens, suggesting an interaction between the influences of estrogen and caffeine use on the risk of PD. To explore a possible biological basis for this interaction, we systematically investigated how the neuroprotective effect of caffeine is influenced by gender, ovariectomy (OVX), and then exogenous estrogen in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of PD. (1) Caffeine treatment produced a dose-dependent attenuation of MPTP-induced striatal dopamine loss in both young and retired breeder (RB) male, but not female, mice. (2) In female mice (both young and RB), caffeine was less potent or altogether ineffective as a neuroprotectant after sham surgery compared to OVX or after OVX plus estrogen replacement compared to OVX plus placebo treatment. (3) Estrogen treatment also prevented the protection of caffeine against dopamine loss in young male mice. (4) Consistent with the putative protective effect of estrogen, female and OVX plus estrogen mice were relatively resistant to MPTP toxicity compared to male and OVX plus placebo mice, respectively. (5) There was no overall difference in brain levels of caffeine and its metabolites between OVX plus placebo and OVX plus estrogen mice. Together, these results suggest that estrogen can occlude and thereby prevent the neuroprotective effect of caffeine in a model of PD neurodegeneration, supporting a biological basis for the interaction between estrogen and caffeine in modifying the risk of PD.
Key words: adenosine A2A receptor; dopamine; gender; methylxanthine; ovariectomy; striatum
Received July 20, 2005;
revised October 20, 2005;
accepted November 21, 2005.
This article has been cited by other articles:

|
 |

|
 |
 
X. Gao, H. Chen, M. A. Schwarzschild, D. B. Glasser, G. Logroscino, E. B. Rimm, and A. Ascherio
Erectile Function and Risk of Parkinson's Disease
Am. J. Epidemiol.,
December 15, 2007;
166(12):
1446 - 1450.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. RAGONESE, M. D'AMELIO, and G. SAVETTIERI
Implications for Estrogens in Parkinson's Disease: An Epidemiological Approach
Ann. N.Y. Acad. Sci.,
November 1, 2006;
1089(1):
373 - 382.
[Abstract]
[Full Text]
[PDF]
|
 |
|